HER2-Negative Breast Cancer Completed Phase 3 Trials for Eribulin (DB08871)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02225470Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesTreatment